|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.520 HKD | -0.91% |
|
+0.62% | +5.50% |
| Feb. 09 | Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | MT |
| Feb. 08 | Sino Biopharm's LM-302 Completes Phase 3 Trial Enrollment in Gastric Cancer Study | MT |
| Capitalization | 103B 117B 14.91B 12.56B 11.46B 10.94B 20.31B 1,350B 21.1B 133B 52.91B 652B 55.91B 54.76B 2,279B | P/E ratio 2025 * |
22.6x | P/E ratio 2026 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise value | 96.9B 110B 14.03B 11.82B 10.78B 10.29B 19.1B 1,270B 19.85B 125B 49.77B 613B 52.6B 51.52B 2,144B | EV / Sales 2025 * |
2.94x | EV / Sales 2026 * | 2.52x |
| Free-Float |
51.86% | Yield 2025 * |
1.48% | Yield 2026 * | 1.5% |
| 1 day | -0.91% | ||
| 1 week | +0.62% | ||
| Current month | -1.81% | ||
| 1 month | -5.64% | ||
| 3 months | -11.53% | ||
| 6 months | -15.43% | ||
| Current year | +5.50% |
| 1 week | 6.43 |  | 6.97 |
| 1 month | 6.15 | | 7.19 |
| Current year | 6.15 | | 7.29 |
| 1 year | 3.15 | | 9.12 |
| 3 years | 2.29 | | 9.12 |
| 5 years | 2.29 | | 9.69 |
| 10 years | 2.05 | | 11.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 30 | 2022-07-27 |
Chun Ling Li
DFI | Director of Finance/CFO | 55 | 1995-12-31 |
Hsin Tse
IRC | Investor Relations Contact | 56 | 2013-04-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping Tse
CHM | Chairman | 74 | 2000-02-01 |
Hsin Tse
BRD | Director/Board Member | 56 | 1995-07-31 |
| Director/Board Member | 62 | 2017-04-09 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.91% | +0.62% | +112.38% | +45.21% | 14.91B | |
| +0.33% | -1.72% | +23.18% | +199.23% | 929B | |
| -0.45% | +1.44% | +55.91% | +50.24% | 587B | |
| +1.76% | +3.61% | +20.03% | +51.71% | 409B | |
| +0.08% | +1.01% | +20.89% | +28.94% | 374B | |
| +1.42% | +7.19% | +26.36% | +32.36% | 320B | |
| +1.08% | +4.32% | +27.98% | +55.61% | 311B | |
| +1.82% | -0.43% | +46.26% | +11.65% | 301B | |
| +1.32% | +5.11% | -45.12% | -37.51% | 219B | |
| +1.52% | -3.94% | +26.80% | +53.17% | 199B | |
| Average | +0.80% | +1.86% | +31.47% | +49.06% | 366.36B | |
| Weighted average by Cap. | +0.74% | +1.58% | +26.89% | +76.62% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.97B 37.31B 4.77B 4.02B 3.67B 3.5B 6.5B 432B 6.75B 42.66B 16.94B 209B 17.9B 17.53B 730B | 36.08B 40.82B 5.22B 4.4B 4.01B 3.83B 7.11B 473B 7.39B 46.68B 18.53B 228B 19.58B 19.18B 798B |
| Net income | 4.83B 5.47B 699M 589M 538M 513M 953M 63.35B 990M 6.25B 2.48B 30.59B 2.62B 2.57B 107B | 4.77B 5.39B 690M 581M 530M 506M 940M 62.49B 976M 6.17B 2.45B 30.18B 2.59B 2.53B 105B |
| Net Debt | -6.1B -6.91B -883M -744M -679M -648M -1.2B -80B -1.25B -7.9B -3.13B -38.63B -3.31B -3.24B -135B | -11.96B -13.53B -1.73B -1.46B -1.33B -1.27B -2.36B -157B -2.45B -15.48B -6.14B -75.72B -6.49B -6.36B -265B |
Employees
23,056
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-13 | 6.520 $ | -0.91% | 24,031,580 |
| 26-02-12 | 6.580 $ | -3.66% | 32,177,640 |
| 26-02-11 | 6.830 $ | +0.59% | 33,724,690 |
| 26-02-10 | 6.790 $ | +2.88% | 79,870,300 |
| 26-02-09 | 6.600 $ | +1.85% | 51,702,870 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
5.762CNY
Average target price
8.737CNY
Spread / Average Target
+51.63%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1177 Stock
Select your edition
All financial news and data tailored to specific country editions
